Menu

Oxford University to Study Marijuana

Academics partner with a biotech firm to investigate cannabinoids and develop potential therapeutics.

Mar 20, 2017
Kerry Grens

PIXABAY, FOTOBIASOxford University in the U.K. and biotech company Oxford Cannabinoid Technologies are launching a new line of research into marijuana’s potential for treating various ailments, including cancer and chronic pain. In the U.S., some states have legalized medical or recreational use of the drug, but marijuana is currently not legal in the U.K.

“Cannabinoid research has started to produce exciting biological discoveries,” Ahmed Ahmed, a professor of Gynaecological Oncology at Oxford University, said in a press release. “This field holds great promise for developing novel therapeutic opportunities for cancer patients.”

In addition to cancer, the co-called Cannabis Research Plan, which will begin with a roughly $12.4 million investment from the biotech firm, will also study cannabinoids’ effects on pain and inflammatory diseases.

Oxford neuroscientist Zameel Cader told The Independent the endocannabinoid system—the signaling pathways that include receptors that detect the psychoactive components of marijuana—is important for both brain function and immune responses. “We know that’s particularly important for many neurological disorders. It’s really an area of huge untapped potential.”

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening